Seres Therapeutics Inc
NASDAQ:MCRB

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
NASDAQ:MCRB
Watchlist
Price: 0.9905 USD 8.19% Market Closed
Market Cap: 169.1m USD
Have any thoughts about
Seres Therapeutics Inc?
Write Note

Seres Therapeutics Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Seres Therapeutics Inc
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Seres Therapeutics Inc
NASDAQ:MCRB
Net Income
-$25.5m
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
-9%
Abbvie Inc
NYSE:ABBV
Net Income
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Seres Therapeutics Inc
Glance View

Market Cap
168.6m USD
Industry
Biotechnology

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

MCRB Intrinsic Value
0.5699 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Seres Therapeutics Inc's Net Income?
Net Income
-25.5m USD

Based on the financial report for Sep 30, 2024, Seres Therapeutics Inc's Net Income amounts to -25.5m USD.

What is Seres Therapeutics Inc's Net Income growth rate?
Net Income CAGR 10Y
-9%

Over the last year, the Net Income growth was 82%. The average annual Net Income growth rates for Seres Therapeutics Inc have been 9% over the past three years , 19% over the past five years , and -9% over the past ten years .

Back to Top